公开(公告)号：EP3274370B1

公开(公告)日：2019-11-20

申请号：EP16713784.3

申请日：2016-03-21

申请人： Bayer Pharma Aktiengesellschaft

发明人： WILLUDA, Jörg ,  TRAUTWEIN, Mark ,  GRITZAN, Uwe ,  FREIBERG, Christoph ,  DITTMER, Frank ,  SCHÖNFELD, Dorian ,  GLÜCK, Julian, Marius ,  PINKERT, Jessica ,  GUTIERREZ Eva-Maria ,  GOLFIER, Sven ,  HOLTON, Simon ,  BECKHOVE, Philip ,  GE, Yingzi

IPC分类号： C07K16/28 ,  A61P35/00

公开(公告)号：EP3274370A2

公开(公告)日：2018-01-31

申请号：EP16713784.3

申请日：2016-03-21

申请人： Bayer Pharma Aktiengesellschaft

发明人： WILLUDA, Jörg ,  TRAUTWEIN, Mark ,  GRITZAN, Uwe ,  FREIBERG, Christoph ,  DITTMER, Frank ,  SCHÖNFELD, Dorian ,  GLÜCK, Julian, Marius ,  PINKERT, Jessica ,  GUTIERREZ Eva-Maria ,  GOLFIER, Sven ,  HOLTON, Simon ,  BECKHOVE, Philip ,  GE, Yingzi

IPC分类号： C07K16/28 ,  A61P35/00

摘要： The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for human and Macaca fascicularis CEACAM6 (Carcinoembryonic antigen-related cell adhesion molecule 6, CD66c, Non-specific crossreacting antigen, NCA, NCA-50/90), and which do not significantly cross-react with the closely related human CEACAM1, human CEACAM3, and human CEACAM5. The invention further provides methods to generate this kind of antibodies. The antibodies, accordingly, can be used to treat cancer and other disorders and conditions associated with expression of the CEACAM6. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.